Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Stem cell therapy for Parkinson's disease: where do we stand?

Roybon, Laurent LU ; Christophersen, Nicolaj LU ; Brundin, Patrik LU and Li, Jia-Yi LU (2004) In Cell and Tissue Research 318(1). p.261-273
Abstract
A major neuropathological feature of Parkinson's disease (PD) is the loss of nigrostriatal dopaminergic neuron. Patients exhibit motor symptoms, including bradykinesia, rigidity, and tremor. Neural grafting has been reported to restore striatial dopaminergic neurotransmission and induce symptomatic relief. The major limitation of cell replacement therapy for PD is the shortage of suitable donor tissue. The present review describes the possible sources of cells, including embryonic stem cells and somatic adult stem cells, both of which potentially could be used in cell therapy for PD, and discusses the advantages and disadvantages of each cell type.
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Parkinson's disease, Neural grafting, Embryonic stem cells, Somatic adult stem cells
in
Cell and Tissue Research
volume
318
issue
1
pages
261 - 273
publisher
Springer
external identifiers
  • wos:000224618200027
  • pmid:15309619
  • scopus:5444236167
ISSN
1432-0878
DOI
10.1007/s00441-004-0946-y
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Wallenberg Neuroscience Centre, Lund (0131000110), Neuronal Survival (013212041), Neural Plasticity and Repair (013210080)
id
1caf6c34-441f-4cc3-835d-a9b0a69f7076 (old id 126710)
date added to LUP
2016-04-01 11:51:49
date last changed
2022-04-20 22:58:03
@article{1caf6c34-441f-4cc3-835d-a9b0a69f7076,
  abstract     = {{A major neuropathological feature of Parkinson's disease (PD) is the loss of nigrostriatal dopaminergic neuron. Patients exhibit motor symptoms, including bradykinesia, rigidity, and tremor. Neural grafting has been reported to restore striatial dopaminergic neurotransmission and induce symptomatic relief. The major limitation of cell replacement therapy for PD is the shortage of suitable donor tissue. The present review describes the possible sources of cells, including embryonic stem cells and somatic adult stem cells, both of which potentially could be used in cell therapy for PD, and discusses the advantages and disadvantages of each cell type.}},
  author       = {{Roybon, Laurent and Christophersen, Nicolaj and Brundin, Patrik and Li, Jia-Yi}},
  issn         = {{1432-0878}},
  keywords     = {{Parkinson's disease; Neural grafting; Embryonic stem cells; Somatic adult stem cells}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{261--273}},
  publisher    = {{Springer}},
  series       = {{Cell and Tissue Research}},
  title        = {{Stem cell therapy for Parkinson's disease: where do we stand?}},
  url          = {{http://dx.doi.org/10.1007/s00441-004-0946-y}},
  doi          = {{10.1007/s00441-004-0946-y}},
  volume       = {{318}},
  year         = {{2004}},
}